Ignite Creation Date:
2025-12-25 @ 3:31 AM
Ignite Modification Date:
2025-12-26 @ 2:13 AM
Study NCT ID:
NCT05488405
Status:
COMPLETED
Last Update Posted:
2023-09-07
First Post:
2022-08-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Sponsor:
Dr. Falk Pharma GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-09
Start Date Type:
ACTUAL
Primary Completion Date:
2023-06-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-07-20
Completion Date Type:
ACTUAL
First Submit Date:
2022-08-03
First Submit QC Date:
None
Study First Post Date:
2022-08-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-06
Last Update Post Date:
2023-09-07
Last Update Post Date Type:
ACTUAL